IOBTQ (IO Biotech) EBITDA Margin %: 0.00% (As of Sep. 2025)


What is IO Biotech EBITDA Margin %?

IO Biotech IOBTQ +27.50% EBITDA Margin % is 0.00% as of Sep. 2025. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, IO Biotech ranks worse than 106044.43% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. IO Biotech's EBITDA for the three months ended in Sep. 2025 was $-8.93 Mil. IO Biotech's Revenue for the three months ended in Sep. 2025 was $0.00 Mil. Therefore, IO Biotech's EBITDA margin for the quarter that ended in Sep. 2025 was 0.00%.

IO Biotech  (OTCPK:IOBTQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

IO Biotech EBITDA Margin % Related Terms

IO Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for IO Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IO Biotech EBITDA Margin % Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IO Biotech Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IOBTQ vs CNBX, ENDV, RGBP: EBITDA Margin % Comparison

For the Biotechnology subindustry, IO Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IO Biotech EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where IO Biotech's EBITDA Margin % falls into.


IO Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

IO Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-94.328/0
= %

IO Biotech's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-8.926/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
IO Biotech (IOBTQ) has a EBITDA Margin % of 0.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IO Biotech and its competitors. According to the industry distribution chart, IO Biotech ranks #999999 out of 943 companies in the Biotechnology industry.
Is IO Biotech's EBITDA Margin % too high?
IO Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, IO Biotech ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does IO Biotech's EBITDA Margin % compare to CNBX and ENDV?
According to the Biotechnology industry distribution chart, IO Biotech ranks #999999 out of 943 companies for EBITDA Margin %. This places IO Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IO Biotech and its competitors. IO Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IO Biotech stock overvalued right now?
IO Biotech (IOBTQ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IO Biotech (IOBTQ), the current EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IO Biotech Business Description

Address Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.